Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activationYasmin Abaza, Guillermo Garcia‐Manero, Carlos E. Bueso‐Ramos et al.|Leukemia Research|2018Cited by 9